REDWOOD CITY, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Genitope Corporation today announced that the company will be presenting at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference in New York City on November 8th, 2005.
The presentation will be given by Dan W. Denney, Jr., Ph.D., chairman of the board and chief executive officer, and John Vuko, vice president and chief financial officer of Genitope Corporation. The presentation is scheduled on Tuesday, November 8, 2005 at 10:10 a.m. ET at the Palace Hotel.
A live audio webcast of Genitope Corporation’s presentation will be accessible on the company’s website at http://www.genitope.com . An archive of the webcast will be available on the website through December 1, 2005.
About Genitope Corporation
Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation’s lead product candidate, MyVax (R) Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient’s tumor and is designed to activate the patient’s immune system to identify and attack cancer cells. Genitope Corporation is conducting a pivotal phase 3 clinical trial using MyVax (R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin’s lymphoma patients. Genitope Corporation is based in Redwood City, California.
Genitope Corporation
CONTACT: Media - Jackie Quintanilla, +1-323-202-1053,Jacqueline.Quintanilla@edelman.com, Lisa Waters, +1-323-202-1051,Lisa.waters@edelman.com, both of Edelman; or Investors - John Vuko, ChiefFinancial Officer of Genitope Corporation, +1-650-482-2000, IR@genitope.com
Web site: http://www.genitope.com/
